Why Are Follow-Ups and Clarifications Still Manually Tracked?
- Sushma Dharani
- Dec 5, 2025
- 6 min read
Pharmacovigilance has advanced dramatically over the past two decades. The industry has witnessed a rapid rise in digital case intake channels, sophisticated signal detection algorithms, and large-scale safety databases. Yet one critical part of the safety workflow continues to rely heavily on manual effort: the tracking, management, and closure of follow-ups and clarifications.
Despite near-universal acknowledgement that follow-ups are essential for complete and accurate case assessment, many safety teams are still using spreadsheets, email threads, shared drives, or tracker documents to handle them. This creates inefficiencies, operational risk, delays in case processing, and inconsistencies in compliance. The question is why this gap persists when the rest of the ecosystem is moving toward automation and structured workflows.
To understand the root of the issue, it is important to unpack the nature of follow-ups and clarifications, the limitations of existing systems, and the operational challenges faced by global safety teams.
The Nature of Follow-Ups and Why They Are Challenging
Follow-ups and clarifications are inherent to pharmacovigilance. They arise because source documents are often incomplete, ambiguous, or inconsistent. Case processing guidelines require a certain level of medical and factual completeness before a case can be finalized. Missing items such as onset dates, outcomes, concomitant medications, pregnancy status, laboratory results, medical history, or reporter credentials trigger follow-up requests.
In theory, follow-ups are straightforward. A missing data point is identified, a request is sent, a response is received, and the case is updated. In practice, they are complex and recursive.
Many challenges contribute to the manual burden:
Fragmented Data Sources: Follow-ups originate from a variety of sources: call centers, medical information teams, affiliates, intake vendors, field staff, patient support programs, social media monitoring, literature surveillance, and healthcare providers. Each source may have its own intake tools, formats, and timelines. Consolidating these in a structured way is difficult.
Unstructured Communication: Follow-ups are often initiated and resolved through free-form communications such as email, phone calls, portal submissions, letters, or PDF reports. Extracting meaning from these manually is time-consuming and error-prone.
Repeated and Cascading Requests: A single follow-up request may lead to a series of back-and-forth clarifications. A response might answer one question but raise another. Tracking these chains manually while keeping cases compliant with expected timelines becomes overwhelming.
Variability in Case Processing Rules: Country regulations, internal guidelines, seriousness criteria, and product-specific requirements influence what constitutes a necessary follow-up. Some items are required only under certain conditions. Determining what to request often depends on reviewer judgement that may vary across teams.
Multiple Stakeholders: Follow-ups involve safety operations teams, medical reviewers, affiliates, vendor partners, call center agents, and sometimes external healthcare professionals. Communication across these groups is not always coordinated, which increases manual workload.
Lack of Prioritization Mechanisms: Not all follow-ups are equal. Some are critical for timelines and aggregate reporting, while others are nice-to-have. Without automated prioritization, teams manually triage them and often struggle with volume.
Audit and Compliance Pressure: Regulatory bodies expect full traceability. Every request, response, rationale, and timeline must be recorded. When follow-ups are tracked manually, teams spend extra time documenting actions to remain compliant.
These realities contribute to why follow-ups remain one of the most resource-intensive parts of case management.
Limitations of Existing Safety Databases and Systems
Pharmacovigilance databases such as Argus, ArisG, and newer cloud-based systems are powerful for storing, processing, and reporting safety cases. However, they were not originally designed as workflow engines for dynamic follow-up management.
Several limitations contribute to continued manual tracking:
Case-Centric Rather Than Workflow-Centric Design: Safety systems focus on the final state of the case: the structured fields, coding, narratives, and regulatory outputs. They lack granular, built-in tooling to orchestrate the micro-tasks involved in follow-up lifecycle management.
Limited Support for Unstructured Inputs: Many follow-up responses arrive as unstructured documents or communications. Standard safety systems cannot parse these automatically, so teams must interpret and enter them manually.
Lack of Real-Time Visibility Across Teams: Affiliates or vendors often work with separate systems or trackers. Updates do not always sync automatically, leading to duplication or missed follow-ups.
Rigid Data Models: Traditional safety databases enforce strict data standards. While critical for regulatory submissions, this rigidity makes it difficult to incorporate custom workflows, context-specific questions, or evolving requirements without manual workarounds.
Gaps in Automation Capabilities: Many systems offer basic reminders or status labels but do not support intelligent task routing, automated data extraction, or natural language understanding. As a result, teams maintain parallel trackers to compensate.
Slow Change Management: Customizing PV systems can be time-consuming, expensive, and subject to long validation cycles. Organizations often defer enhancements and fall back on manual processes.
Because of these constraints, safety teams continue to rely on spreadsheets or shared documents to manage follow-ups, even when the core safety database is otherwise highly automated.
Operational Realities That Perpetuate Manual Tracking
Beyond technology limitations, organizational and operational factors also contribute to the persistence of manual tracking.
Volume and Variability: Large biopharma companies may process hundreds of thousands of cases annually. Even a small percentage requiring follow-up can create enormous manual volume. The inconsistency in reporter behavior makes automation difficult.
Global Workflows: Follow-ups must pass through multiple regions, languages, and time zones. Manual oversight becomes a default safeguard to ensure nothing is missed.
Vendor Partnerships: Outsourced case processing models often distribute responsibilities between internal teams and external partners. When processes are not aligned, manual trackers emerge to bridge gaps.
Regulatory Risk Aversion: Safety teams are cautious about introducing automation into areas closely linked to compliance timelines. Many keep manual oversight as a buffer to reduce the risk of missing critical information.
Incremental Digital Transformation: Organizations often implement digital improvements in phases. Follow-ups may sit outside the scope of early transformation programs, leaving them dependent on legacy practices.
Human Interpretation Requirements: Medical judgement is frequently required to determine whether data is sufficient or if another follow-up is needed. Manual processes remain entrenched because they appear to give teams more control.
In sum, follow-ups sit at the intersection of complex data, multi-stakeholder collaboration, and regulatory sensitivity. This combination has made full automation challenging, keeping manual tracking as the default.
The Hidden Cost of Manual Follow-Up Management
Although manual tracking persists, it comes with significant operational and compliance risks.
Delays in Case Closure: Manually coordinating requests slows down the overall case workflow, contributing to backlog accumulation.
Inconsistent Data Quality: Information can be lost, misinterpreted, or duplicated when handled through spreadsheets or emails.
Compliance Gaps: Missing documentation, unclear rationale, or delayed follow-ups create audit findings and regulatory exposure.
Inefficient Resource Allocation: Highly skilled pharmacovigilance professionals spend time on administrative tasks instead of medical assessment or quality oversight.
Lack of Centralized Visibility: Leaders and quality teams struggle to assess follow-up volumes, trends, bottlenecks, and performance metrics without consolidated dashboards.
Scalability Issues: As safety case volumes fluctuate due to new products, expansions, or unexpected events, manual processes strain rapidly.
These challenges underscore the need for intelligent solutions capable of modernizing follow-up workflows.
How Tesserblu Can Help
Tesserblu addresses the core issues that cause follow-ups and clarifications to remain manually tracked. Rather than attempting to replace safety databases, Tesserblu enhances and modernizes follow-up workflows through intelligent automation, advanced orchestration, and interoperability.
Here is how Tesserblu transforms follow-up management:
Centralized, Structured Follow-Up Workflow Engine: Tesserblu consolidates follow-ups into a single environment. No more scattered spreadsheets or email trackers. Every follow-up request, response, reminder, and closure is synchronized and visible to all relevant stakeholders.
Automated Identification of Missing Information; The platform uses rule-based and AI-assisted logic to detect incomplete or inconsistent case data. It highlights required follow-ups based on product-specific, regulatory, and internal criteria, reducing guesswork and human error.
Intelligent Routing and Task Assignment: Tasks are automatically assigned to the appropriate teams or affiliates based on case attributes, seriousness, region, or workflow stage. This reduces manual coordination and ensures timely follow-up execution.
Natural Language Processing for Unstructured Inputs: Tesserblu can interpret free-text emails, call notes, documents, or PDFs, extracting relevant details and mapping them to the case. This directly reduces the most time-consuming part of manual follow-up handling.
Automated Reminders and Timelines: The system generates reminders and alerts based on predefined business rules, preventing overdue tasks and minimizing compliance risks.
Complete Audit Trail: Every action taken throughout the follow-up lifecycle is recorded. This ensures traceability and simplifies audit preparedness without manual documentation effort.
Real-Time Dashboards and Insights: Managers can view the status of all follow-ups across regions, products, and vendors. Bottlenecks become visible immediately, enabling data-driven operational decisions.
Seamless Integration with Safety Databases: Tesserblu integrates with existing systems such as Argus or ArisG, allowing real-time exchange of case updates and follow-up information. This means organizations can modernize without system overhauls.
Scalable to Global Volume and Complexity: Whether a company handles thousands or hundreds of thousands of cases, Tesserblu adapts to the operational scale while maintaining consistency and control.
Reduced Dependence on Manual Oversight: By automating administrative tasks and enabling intelligent decision support, Tesserblu frees pharmacovigilance teams to focus on case quality and medical judgement.
Through these capabilities, Tesserblu eliminates the reliance on spreadsheets and fragmented trackers, moving follow-up workflows into a modern, automated, and compliant framework.
Conclusion
Follow-ups and clarifications are essential for accurate and compliant pharmacovigilance. Yet they remain one of the most manually intensive aspects of case management due to fragmented data sources, unstructured communication, system limitations, and operational complexity. Manual tracking persists because traditional safety systems were not designed to manage dynamic follow-up workflows.
The cost of this manual burden is significant in terms of efficiency, compliance, quality, and scalability. To meet modern pharmacovigilance demands, organizations need intelligent solutions that streamline, automate, and orchestrate the entire follow-up lifecycle.
Tesserblu fills this gap by providing a dedicated, intelligent workflow engine built to modernize follow-up management without replacing existing safety systems. Through automation, NLP capabilities, structured workflows, and real-time visibility, Tesserblu helps safety teams eliminate operational inefficiencies and elevate the overall quality of pharmacovigilance. Book a meeting if you are interested to discuss more.
Comments